Trials
3 active
10 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Generalized Anxiety Disorder (GAD), Bipolar I or II Disorder, Bipolar Disorder
- Main trialPhase 2
- “Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs. ABBV-932 is an investigational drug being developed for the adjunctive treatment of GAD. Participants will be randomly assigned to receive ABBV-932 or Placebo in addition to their currently prescribed ADTs. There is 1 in 3 chance of participants…”In the company’s words, NCT06846320 on ClinicalTrials.gov
Other drugs for Generalized Anxiety Disorder (GAD)
- ITI-1284Intra-Cellular Therapies, Inc. · Phase 3
- SEP-363856Otsuka · Phase 3
- BuagafuranBeijing Union Pharmaceutical Factory Ltd · Phase 3
- DT120Definium Therapeutics US, Inc. · Phase 3
- Shugan JieyuSichuan Jishengtang Pharmaceutical Co., Ltd. · Phase 3
- SYT-510Synendos Therapeutics AG · Phase 2
Coming up3
- NovPhase 2 trial completes · ClinicalTrials.gov
- Feb 2027Phase 1 trial completes · ClinicalTrials.gov
- Mar 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Nov 2026 | Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | |
| Phase 2Active, not recruiting | Mar 2027 | Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder | |
| Phase 1Recruiting | Feb 2027 | A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar Disorder | |
| Phase 2Completed | 12 Nov 2025 | Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder | |
| Phase 1Completed | 31 May 2024 | Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants | |
| Phase 1Completed | 4 Mar 2025 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD) | |
| Phase 1Completed | 26 May 2025 | Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy Volunteers | |
| Phase 1Completed | 8 Dec 2025 | Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult Chinese Participants | |
| Phase 1Completed | 8 May 2026 | A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants | |
| Phase 1Completed | 14 Sep 2026 | A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026